New medicines are increasingly targeting the genetic drivers of disease. But what if medicine could go further and correct the genetic defect itself? » Read More
The Obama administration said recently that more than 11 million have signed up for health insurance. Experts see it differently.
Updated guidelines warn that consuming any amount of alcohol increases the risk to your health.
Mount Sinai Hospital's CEO told CNBC that while Obamacare survived a repeal attempt, it's locked in a tough game of numbers.
Virtual reality is the newest tech toy, but dizziness and other side effects could derail the momentum, says Doug Magyari.
Researchers have found that blocking a receptor in the brain that regulates immune cells could benefit the treatment of Alzheimer's.
An unknown number of Fitbit accounts reportedly have been breached by unidentified people who changed their settings.
A report commissioned by NASA discusses the risks of one of the agency's big goals: more human space travel.
Martin Shrekli is using a brokerage account to secure his $5 million bond to keep him out of jail as he fights fraud charges.
The Obama administration is looking to draw in more uninsured customers as open enrollment nears its Jan. 31 deadline.
Valeant Pharmaceuticals on Wednesday named Howard Schiller interim chief executive officer, effective immediately.
There hasn't been a significant increase in part-time jobs due to the Affordable Care Act.
Lumosity claimed its brain games could improve mental performance and stave off age-related cognitive decline.
Chipotle warned investors in a filing Wednesday that its comparable-restaurant sales nosedived 14.6 percent in the fourth quarter.
Martin Shkreli was accused by an ex-employee of contacting the man's family repeatedly during a lawsuit.
Want to stay healthy? These are the top 11 apps prescribed by doctors in the Ochsner Health System.
Here are how some food-related stocks are moving on news of an avian flu outbreak in Iowa.
The sheer volume and pace of biotech offerings are causing some to question whether the sector is nearing the end of its years of buoyancy.
Executives at J.P. Morgan's healthcare conference discuss the technologies they believe with change medicine as we know it.
Biopharma executives at the J.P. Morgan Healthcare Conference talk about this year's biggest challenges.
Ariad CEO Harvey Berger, tells CNBC's Meg Tirrell commercially the company had a good year and provides insight into its new cancer drug, Iclusig.
Get the best of CNBC in your inbox